NIH suspends SELECT
This article was originally published in The Tan Sheet
Executive Summary
The National Institutes of Health suspends research on whether vitamin E and selenium supplements prevent prostate cancer after prostate cases increased among the subjects taking only vitamin E and cases of adult onset diabetes increased in those taking selenium. The National Cancer Institute says Oct. 27 that data from the Selenium and Vitamin E Cancer Prevention Trial showed "small but not statistically significant" increases in the two conditions. NCI adds that "neither of these findings proves an increased risk from the supplements and both may be due to chance." The Southwest Oncology Group coordinated SELECT at more than 400 sites (1"The Tan Sheet" March 21, 2005, p. 13). More than 35,000 men aged 50 and older were randomly assigned to take selenium and vitamin E; selenium and a placebo; vitamin E and a placebo; or two placebos. NCI will advise SELECT participants to stop taking the supplements
You may also be interested in...
Vitamin E Study Rules Out Cancer Prevention, Suggests Heart Risk Link
Vitamin E manufacturers hoping for positive clinical news may have to wait for data from future trials, such as an NIH-sponsored prostate cancer prevention study, in the wake of another negative study published in the March 16 Journal of American Medical Association
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.